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Introduction
Ewing’s sarcoma family tumors (ESFTs) are a group of 
mostly undifferentiated, highly aggressive, small round-
cell  tumors  affecting  mostly  children  and  adolescents, 
with a peak incidence around 15 years of age [1]. Their 
origin has been a matter of debate ever since they were 
first  described  in  1921  by  James  Ewing  [2].  Although 
presenting predominantly as a neoplasm of the bone, the 
exact  tumor  histogenesis  remains  poorly  defined,  and 
rare  occurrences  in  the  soft  tissue  of  other  organs  [3] 
point to a pluripotent migratory cell of origin.
The unifying genetic trait of this family of tumors is a 
chromosomal  translocation,  t(11;22)(q24;q12),  that  was 
first described more than 20 years ago [4] and molecularly 
elucidated  in  1992  [5].  The  genomic  rearrangement 
results in the fusion of two genes, EWS and FLI1. EWS 
encodes  a  RNA-binding  protein  that  associates  with 
components of the basal transcriptional machinery [6-8] 
and  post-transcriptional  RNA  processing  [9-12],  and 
EWS knockout mice are deficient in homologous recom-
bination and recombination repair [13]. FLI1 encodes a 
member of the ETS protein family, a group of winged 
helix-loop-helix  transcription  factors  sharing  a  DNA-
binding domain with specificity for GGAA/T core motifs. 
In the ESFT-specific EWS/FLI1 fusion protein, the EWS 
RNA-binding  domain  is  replaced  by  the  FLI1  DNA-
binding domain, thus creating a novel ETS transcription 
factor with unique properties. In about 10-15% of ESFTs, 
one  of  four  related  ETS  transcription  factors  (ERG, 
ETV1, ETV4 or FEV) substitutes for FLI1 in alternative 
but identically structured EWS fusion proteins [14].
EWS/FLI1 shapes the ESFT phenotype
Functional  studies  of  ectopically  expressed  EWS/FLI1 
using promiscuous ETS binding sites to drive reporter 
gene  activity  revealed  that  the  amino-terminal  EWS 
domain  contributes  strong  transcriptional  activation 
properties  to  EWS/ETS  fusion  proteins  [15-17].  Early 
expression profiling studies of EWS/FLI1-transduced cell 
line  models  confirmed  that  a  plethora  of  genes  are 
upregulated by the fusion protein. However, an almost 
equal  number  of  genes  were  consistently  found  to  be 
repressed [18-21]. These approaches did not discriminate 
between  direct  and  indirect  activities  of  the  chimeric 
oncogene  and  thus  the  EWS/FLI1-dependent  mecha-
nisms  underlying  aberrant  gene  expression  in  these 
model  systems  remained  elusive.  They  also  did  not 
account  for  the  fact  that  tolerance  to  EWS/FLI1 
expression and the pattern of responsive genes depends 
on the cellular context [22].
A  common  observation  in  these  studies  was  that 
ectopic  EWS/FLI1  imposed  neuronal  and  endothelial 
features  of  gene  expression  on  non-ESFT  cells  [19,22]. 
These results may provide a molecular explanation for 
James  Ewing’s  original  phenotypic  classification  of  the 
entity as “endothelioma of the bone” [2], which was later 
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1980s. It also provides a mechanistic foundation for the 
prevailing  immunohistochemistry-based  view  of  the 
1990s of a neuroectodermal origin of the disease, which 
was  strengthened  by  anecdotal  reports  about  chemo-
therapy- or experimentally-induced neural differentiation 
of ESFT cells.
Mesenchymal origin of ESFT and the EWS/FLI1 
signature
The profiling data obtained from models that ectopically 
express EWS/FLI1 have suggested that partial endothelial 
and neural differentiation are a consequence of the trans-
criptional  activity  of  the  fusion  oncogene,  largely 
independent of the histological background. This hypo-
the  sis  obtained  support  when  it  became  possible  to 
modulate  endogenous  EWS/FLI1  expression  in  ESFT 
cells by means of RNA interference.
Among studies that used this approach, two investi  ga-
tions also considered gene expression of primary ESFTs 
in comparison with a series of normal human tissues and 
arrived at a similar conclusion: the tissue whose expres-
sion is most similar to that shown by ESFTs when EWS/
FLI1  is  turned  off  is  mesenchymal  progenitor  cells 
(MPCs)  [23,24].  Tirode  et  al.  [24]  demonstrated  that 
although ESFT cells are blocked in their differentiation 
potential  towards  adipogenic  and  osteogenic  lineages, 
they  regain  pluripotency  upon  long-term  inhibition  of 
EWS/FLI1  expression.  This  finding  is  consistent  with 
earlier experimental results that demonstrated the block-
age  of  mesenchymal  differentiation  potential  of  EWS/
FLI1-transformed  MPCs  [25]  and  the  acquisition  of 
ESFT-like gene expression and tumorigenic properties of 
these  cells  in  mice  [26,27].  Kauer  and  colleagues  [23] 
demonstrated that, when MPCs are chosen as a reference 
tissue, most differences in gene expression of ESFTs are 
caused by the expression of EWS/FLI1, with few excep-
tions. On the basis of this comparison, an ESFT-specific 
EWS/FLI1 gene expression signature was obtained. At a 
significance  level  of  P  =  0.1,  344  and  237  genes  were 
found to be up- and down-regulated by the fusion onco-
gene,  respectively.  Interestingly,  only  a  third  of  EWS/
FLI1-induced  genes  and  a  fifth  of  the  repressed  genes 
from  this  single-platform  analysis  overlapped  with  a 
signature  previously  published  by  Hancock  et  al.  [28], 
which  was  based  on  a  meta-analysis  of  EWS/FLI1-
dependent  gene  expression  in  various  models  and 
analyzed  on  various  expression-profiling  platforms. 
Although there was a strong overall overlap in the gene 
lists affected by EWS/FLI1, about 80% of the EWS/FLI1 
signature genes in the earlier study [28] did not achieve 
the significance threshold of the Kauer analysis [23], and 
70%  of  the  Kauer  signature  [23]  was  not  found  to  be 
significant in the Hancock dataset [28]. This discrepancy 
is probably due to the use of different reference tissues, 
given  that  the  Hancock  study  [28]  compared  ESFT-
specific gene expression with the mean of many tissues. 
This  corroborates  the  importance  of  considering  the 
influence of the cellular background in the interpretation 
of EWS/FLI1 target gene studies. It also highlights the 
necessity  of  choosing  an  adequate  reference  tissue  for 
target validation in primary ESFT.
With an incidence of 1.3 per million population, ESFTs 
are  rare  tumors  [29].  Diagnostic  samples  are  most 
frequently obtained by fine needle biopsy and, therefore, 
adequate materials for genomic studies are often difficult 
to obtain. However, the establishment of a reliable gene 
expression  signature  for  ESFT  and  the  validation  of 
robustly EWS/FLI1-regulated genes require the analysis 
of  large  cohorts  of  primary  tumors  from  untreated 
patients on a single analysis platform. Such series are not 
common within a single institution. So far there are only 
four  expression  datasets  from  comparable  screening 
platforms (Affymetrix HGU-133-A and HGU-133-PLUS2) 
publicly  available,  together  comprising  almost  100 
tumors [24,30-32]. These data are a valuable resource for 
target  validation  studies.  However,  only  two  of  these 
datasets are linked to clinical parameters [31,32]; one has 
been used to define a prognostic signature suggesting a 
role  for  the  glutathione  metabolic  pathway  in  chemo-
therapy resistance [32]. This and similar future studies 
will require independent confirmation on clinically well-
annotated tumors from large, uniformly treated patient 
cohorts. Thus, the field of ESFT research is likely to profit 
tremendously  from  the  ongoing  multicentric  European 
and  Children’s  Oncology  Group  clinical  trials  being 
successful in generating and depositing gene expression 
data linked to stage and outcome information on their 
patient cohorts in publicly accessible data banks.
A role for EWS/FLI1 in post-transcriptional gene 
regulation?
Ideally,  ESFT  gene  expression  data  banks  should  also 
contain raw data from analyses on exon arrays to account 
for  variations  in  alternative  splicing  and/or  promoter 
usage. Previous experimental studies have demonstrated 
that EWS/FLI1 can affect 5’ splice site selection in vitro 
[33],  and  the  first  example  of  EWS/FLI1-dependent 
trans  cription-coupled  alternative  splicing  in  ESFT  was 
described for its direct target gene cyclin D1 [9,34]. This 
finding  was  not  unexpected  given  the  multiple 
interactions of the fusion oncogene with components of 
the splicing machinery inherited from the parental EWS 
protein [35-37]. Given that the FLI1 DNA-binding domain 
recruits  these  factors  to  its  chromatin  targets  through 
interaction  with  the  EWS  amino-terminal  domain,  it  is 
likely  that  the  number  of  alternatively  spliced  tumor-
specific EWS/FLI1 targets identified will increase as soon 
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Even  more  information  about  the  abundance,  identity 
and structure of ESFT-specific mRNA and non-coding 
RNA  species  will  be  gained  upon  application  of  next-
generation sequencing technology to the analysis of the 
ESFT transcriptome. Exon-based analysis will shed light 
on  the  poorly  understood  link  between  transcriptional 
and  post-transcriptional  control  of  gene  regulation  by 
EWS/FLI1.
Lessons from the analysis of EWS/FLI1 chromatin 
interactions
So  far,  the  use  of  next-generation  sequencing  for  the 
analysis  of  EWS/FLI1  binding  regions  in  the  ESFT 
chroma  tin  has  yielded  surprising  results:  whereas 
previous chromatin immunoprecipitation (ChIP) studies 
followed  by  gene-specific  PCR  (ChIP-PCR)  identified 
EWS/FLI1  binding  in  proximal  promoter  and  intronic 
regions  of  specific  targets,  including  TNC  [38],  Id2, 
cMYC, CCND1 and TGFBR2 [39], CDKN1A [40], IGFBP3 
[41], PTPL1 [42], STYXL1 [43], AURKA and AURKB [44], 
GLI1  [45]  and  EZH2  [46],  the  first  published  next-
generation sequencing study of genomic DNA recovered 
by  ChIP  (ChIP-seq)  using  a  FLI1-specific  antibody 
detected  EWS/FLI1  binding  sites  in  ESFT  chromatin 
predominantly  far  away  from  the  transcriptional  start 
sites of genes, with a mean distance of 242 kb and up to 
3 Mb [47]. More than half of the EWS/FLI1 binding sites 
were  localized  to  intergenic  regions.  Strikingly,  104  of 
246 identified binding regions consisted of microsatellites 
comprising three or more GGAA repeats, the core ETS 
binding  motif  [47].  This  result  was  consistent  with 
previous ChIP-chip (hybridization of ChIP products to 
DNA microarrays) results obtained with the same anti-
body, which also identified GGAA microsatellites as highly 
over-represented among EWS/FLI1 binding regions [48].
The  authors  of  the  two  studies  [47,48]  attempted  to 
functionally validate the potential transcription enhanc-
ing activity of GGAA microsatellites in response to EWS/
FLI1 by testing multimers of the GGAA core motif in 
luciferase reporter assays [49]. The discovery that GGAA 
microsatellites are associated with EWS/FLI1 protein in 
ESFT  chromatin  and  have  the  potential  to  drive  gene 
transcription when directly fused to a minimal promoter 
in in vitro assays was a new and exciting addition to a 
growing  body  of  evidence  supporting  the  idea  that 
sequences previously considered as genomic ‘junk’ might 
indeed  have  important  functions  [50].  The  question 
remains  whether  binding  to  these  elements  in  the 
chromatin  context  is  sufficient  to  activate  gene  trans-
cription  from  a  distance  of  several  hundred  kilobases, 
and whether this is the predominant mode of aberrant 
gene  regulation  by  the  oncogene  in  ESFT.  Functional 
proof  that  the  observed  EWS/FLI1  binding  to  such 
microsatellites  affects  gene  regulation  in  vivo  requires 
testing  of  endo  ge  nous  gene  activity  following  targeted 
deletion of the respective microsatellite from the genomic 
region in living cells. Furthermore, the identification of 
genes  regulated  by  this  putative  ‘enhancer-type’ 
mechanism is complicated by the fact that a majority of 
EWS/FLI1  binding  GGAA  microsatellites  localize  to 
intergenic  regions  and  cannot  be  assigned  to  specific 
genes.  There  fore,  the  functional  impact  of  this 
observation remains to be defined.
When comparing gene expression signatures of EWS/
FLI1 with the published ChIP-chip and ChIP-seq results, 
less than 10% of EWS/FLI1-regulated genes were found 
to be binding targets by these methods [23], suggesting 
that  either  the  vast  majority  of  EWS/FLI1-responsive 
genes are indirectly regulated or a large number of direct 
EWS/FLI1 targets were missed. From a mechanistic point 
of  view,  repetitive  DNA  sequences  with  high  GGAA 
content may be high affinity binding sites for the chimeric 
ETS  transcription  factor  and,  therefore,  ChIP-based 
identi  fication procedures may selectively enrich for these 
genomic  regions.  In  fact,  an  unpublished  ChIP-seq 
analysis (Bilke S, Kauer M, Kovar H, Meltzer P, personal 
communication),  which  increases  the  number  of 
sequencing reads for EWS/FLI1 more than 30-fold over 
the  previously  published  Guillon  et  al.  study  [47], 
identified  almost  equal  amounts  of  EWS/FLI1  binding 
sites close to transcriptional start sites of genes and in 
intragenic regions (over 4 kb from the TSS). Importantly, 
all previously identified (microsatellite) binding regions 
were also found. Given that, in this study (Bilke et al., 
personal communication), the number of binding regions 
increased  with  the  number  of  sequencing  runs 
performed, and several previously identified direct EWS/
FLI1 target promoters were recovered only with increas-
ing runs, it is possible, although unproven, that promoter 
hits  harboring  only  few  ETS  binding  motifs  be  low-
affinity  binding  sites  for  the  fusion  oncogene,  whereas 
GGAA microsatellites are more strongly bound.
Mechanisms of EWS/FLI1-driven gene regulation 
and functions
Direct  binding  of  EWS/FLI1  to  proximal  promoter 
regions has been inferred from the in silico analysis of 
upstream  regulatory  regions  of  EWS/FLI1  signature 
genes, which were found to be significantly enriched in 
bona fide ETS binding motifs [23]. Unpublished kinetic 
studies  of  gene  expression  on  inducible  EWS/FLI1 
knock  down in ESFT cell lines (Kauer M, Schwentner R, 
Walker RL, Meltzer P, Kovar H, personal communication) 
have  revealed  that  CGGAAT  motifs  are  particularly 
enriched in early down-regulated genes, identifying them 
as candidates for being directly activated by EWS/FLI1. 
Interestingly, upon EWS/FLI1 knockdown, this group of 
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binding motifs for the transcription factors E2F, NRF1 
and NFY, suggesting transcription factor cooperation in 
EWS/FLI1-driven  gene  activation;  this  remains  to  be 
experimentally  tested  [23].  In  addition,  the  ChIP-seq 
study by Guillon et al. [47] identified frequent occurrence 
of combinations of two ETS binding sites in non-micro-
satellite  EWS/FLI1  binding  regions,  providing  the  first 
evidence that the chimeric oncoprotein might activate gene 
transcription from at least some promoters as a homo- or 
heterodimer with other ETS transcription factors.
In contrast, EWS/FLI1-repressed genes did not show 
any  enrichment  of  ETS  binding  motifs  in  the  in  silico 
analysis  [23]  or  in  the  ChIP-seq  study  [47].  Instead, 
binding motifs for a large number of other transcription 
factors were identified in the upstream regulatory regions 
of these genes [23]. These results suggest that the mecha-
nism of EWS/FLI1-mediated gene repression is indirect.
One such mechanism has been identified that involves 
the EWS/FLI1-activated gene NKX2.2, which encodes a 
dual-function  homeodomain  transcription  factor  [51]. 
NKX2.2  transcriptional  repression  functions  through 
recruit  ment  of  Groucho-family  corepressors.  Following 
knock  down of endogenous NKX2.2 expression in ESFT 
cell lines, constructs lacking the transactivation domain 
but retaining the DNA binding and the transcriptional 
repression  domains  were  able  to  rescue  anchorage-
independent growth. About half of 159 NKX2.2-down-
regulated  genes  overlapped  with  EWS/FLI1-repressed 
genes in ESFT cell lines [51].
Another intriguing mode of EWS/FLI1-induced gene 
repression may involve epigenetic mechanisms because 
several genes that encode histone-modifying enzymes are 
among  EWS/FLI1-activated  targets.  One  of  them,  the 
histone methyl transferase Enhancer of Zeste homolog 2 
(EZH2)  gene,  has  only  recently  been  confirmed  [46]. 
EZH2, as the enzymatic subunit of the polycomb PRC2 
complex, methylates histone H3 Lys27, thereby mediating 
gene silencing. Silencing of EZH2 in ESFT cells resulted 
in a generalized loss of methylation on H3 Lys27 as well 
as an increase in H3 acetylation, leading to gene activa-
tion [52].
Other  mechanisms  of  gene  repression  mediated  by 
EWS/FLI1 may emerge from the identification of micro-
RNAs (miRNAs) regulated by EWS/FLI1 in ESFTs. Our 
own preliminary data suggest about 30 miRNAs that are 
both modulated in response to EWS/FLI1 knockdown in 
several  ESFT  cell  lines  and  aberrantly  expressed  in 
primary ESFTs when compared with MPCs. However, to 
fully  appreciate  the  role  of  these  miRNAs  in  ESFT-
specific gene expression, large-scale proteomic data for 
ESFTs  will  be  required,  because  most  miRNAs  are 
thought to affect protein translation rather than mRNA 
levels.
The  gene  sets  repressed  and  activated  by  EWS/FLI1 
differ not only in the mechanisms of regulation by the 
chimeric  oncogene,  but  also  in  their  biological  conse-
quen  ces. Functional annotation of the EWS/FLI1 signa-
ture  genes  revealed  that  activated  genes  are  predomi-
nantly  involved  in  growth-related  functions,  including 
proliferation and energy metabolism, consistent with an 
enrichment  of  sites  for  the  cell-cycle-promoting 
transcription factor E2F in EWS/FLI1-induced genes and 
with the fast growth of ESFTs. In contrast, the functions 
of EWS/FLI1-repressed genes include developmental and 
signaling processes [23]. These results are consistent with 
the highly undifferentiated phenotype of ESFT cells and 
their inability to differentiate in response to adipogenic 
and osteogenic stimuli.
Thus, EWS/FLI1 combines in a single molecule two key 
functions of oncogenic transformation - activated proli-
fera  tion and differentiation arrest - by different mecha-
nisms. Is this a sufficient condition to trigger malignant 
transformation and tumorigenicity of the ESFT precursor 
cell?
Second hit mutations in the development of ESFT
Riggi et al. [26] introduced EWS/FLI1 as a single onco-
gene in MPCs from C57BL/6 mice and transplanted them 
subcutaneously into severe combined immunodeficiency 
(SCID) mice, which lack an immune system; this resulted 
in rapid (within 6 weeks) tumor formation. This finding 
suggests  that,  in  mice,  no  other  mutations  may  be 
required for EWS/FLI1-induced tumorigenesis. In con-
trast, although it has been shown that EWS/FLI1 (and 
also EWS/ERG) transgenic mice can develop neoplasms 
without additional impairment of the tumor suppressor 
p53,  latencies  were  extremely  long  [53-55].  Similarly, 
although introduction of EWS/FLI1 into human MPCs 
resulted  in  a  small  round-cell  phenotype  and  a  trans-
criptional profile similar to ESFTs, these cells were not 
fully  transformed,  retained  their  ability  to  differentiate 
toward  the  chondrocytic,  osteocytic  and  adipocytic 
lineages, and did not form tumors in mice [27]. These 
results may suggest that, in humans, additional genetic 
events  other  than  EWS/FLI1  are  required  to  cause 
tumorigenesis.
Although it has been known for a long time that the 
number of chromosomal aberrations in ESFT is usually 
small,  a  recent  cytogenetic  study  [56]  and  the  only 
published array comparative genome hybridization study 
[57]  both  identified  both  numerical  and  structural 
secondary  aberrations  in  about  80%  of  patients. 
Consistent with earlier studies [58,59], the predominant 
numerical  aberrations  were  trisomies  8  and  12,  which 
were seen in about half and a third of patients, respec-
tively, as well as gains of chromosomes 2 and 1q. So far, 
no candidate aberrantly expressed or mutated genes on 
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first study that used ChIP to identify EWS/FLI1 target 
genes on a genome-wide scale found an enrichment of 
EWS/FLI1-activated genes on chromosome 8, suggesting 
that trisomy may further increase gene dosage of these 
targets  [43].  Structural  aberrations  consisted  mainly  of 
losses  at  1p36,  9p21,  16q2  and  17p13,  suggesting  the 
involvement of tumor-suppressor genes in these regions. 
Copy-number alterations at 9p21 and 17p13 have been 
associated with loss of the tumor-suppressor gene INK4A 
and  mutations  in  p53  at  frequencies  of  approximately 
25%  and  less  than  10%,  respectively  (for  a  review,  see 
[60]).  Potential  tumor  suppressors  involved  in  ESFT 
pathogenesis on chromosomes 1p36 and 16q remain to 
be defined.
Conclusions
Although  the  histogenetic  origin  of  ESFTs  and  the 
mechanisms  of  EWS/FLI1-driven  oncogenesis  have 
started to crystallize from the genomic studies performed 
on  ESFTs  so  far,  many  questions  remain,  posing  a 
challenge for future therapeutic exploitation.
Although EWS/FLI1 was found to be the major driver 
of ESFT oncogenesis, genetic and environmental factors 
influencing  EWS/FLI1  levels  and  activity  remain  to  be 
identified.  Relevant  small  nucleotide  or  copy-number 
polymorphisms  may  be  discovered  in  genome-wide 
association studies, and these might ultimately require a 
community  effort  to  be  successful.  With  respect  to 
environmental factors, a recent unpublished study (Aryee 
DNT, Niedan S, Kauer M, Schwentner R, Bennani-Baiti 
IM,  Ban  J,  Muehlbacher  K,  Kreppel  M,  Walker  RL, 
Meltzer  P,  Poremba  C,  Kofler  R,  Kovar  H,  personal 
communication) demonstrated that ESFTs are frequently 
hypoxic in patients and that in vitro low oxygen modu-
lates  EWS/FLI1  protein  levels  and  the  expression  of 
signature genes in ESFT cell lines in a manner dependent 
on  the  transcription  factor  hypoxia-inducible  factor  1 
(HIF-1α). EWS/FLI1 has also been demonstrated to be 
post  translationally  modified  by  phosphorylation  [61], 
and  addition  of  N-acetylglucosamine  (GlcNAc)  affects 
the  transcriptional  activity  of  the  fusion  protein  [62]. 
Therefore,  pharmacological  inhibitors  of  enzymes 
respon  sible  for  these  modifications,  such  as  glutamine 
analogs that inhibit UDP-GlcNAc biosynthesis, may hold 
promise  as  intriguing  additions  to  current  polychemo-
therapy of ESFT [62]. However, the upstream signaling 
pathways responsible for post-translational modifications 
of EWS/FLI1 have not yet been defined.
It  is  intriguing  to  speculate  that  microenvironmental 
factors might influence EWS/FLI1 expression or activity 
in the tumor tissue directly, via translational (miRNAs) 
or  post-translational  mechanisms,  or  indirectly,  via 
modulation  of  cooperating  transcription  factors.  Such 
factors  may  affect  tumor  aggressiveness  and  prognosis 
and have a role in therapy resistance and relapse. The lack 
of  knowledge  about  these  in  vivo  factors  may  be  the 
reason  why  a  drug  (cytarabine)  that  modulates  EWS-
FLI1  protein  levels  in  vitro,  as  shown  by  a  small 
compound screen based on EWS/FLI1 signatures, has so 
far  failed  to  show  any  significant  therapeutic  activity 
against ESFTs in patients [63,64]. Thus, further genomic 
studies, particularly on large cohorts of clinically well-
annotated  primary  tumors,  and  also  post-genomic 
investigations  on  signaling  pathways  in  ESFT,  are 
warranted  to  appreciate  the  impact  of  genetic  and 
microenvironmental variations. Ultimately, the emerging 
knowledge may be translated into a better staging of the 
disease  and  the  development  of  new  drugs  interfering 
with EWS/FLI1 activity and consequently tumor growth.
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